First Midwest Bank Trust Division decreased its position in shares of HCP, Inc. (NYSE:HCP) by 1.1% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 29,955 shares of the real estate investment trust’s stock after selling 342 shares during the quarter. First Midwest Bank Trust Division’s holdings in HCP were worth $1,067,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Marshall Wace North America L.P. purchased a new stake in HCP in the first quarter worth about $182,000. Advisory Services Network LLC lifted its holdings in shares of HCP by 1,599.7% during the first quarter. Advisory Services Network LLC now owns 24,713 shares of the real estate investment trust’s stock valued at $774,000 after purchasing an additional 23,259 shares during the last quarter. Nordea Investment Management AB lifted its holdings in shares of HCP by 14.3% during the first quarter. Nordea Investment Management AB now owns 27,094 shares of the real estate investment trust’s stock valued at $848,000 after purchasing an additional 3,384 shares during the last quarter. Amundi Pioneer Asset Management Inc. lifted its holdings in shares of HCP by 17.5% during the first quarter. Amundi Pioneer Asset Management Inc. now owns 555,436 shares of the real estate investment trust’s stock valued at $17,384,000 after purchasing an additional 82,719 shares during the last quarter. Finally, Pensionfund DSM Netherlands lifted its holdings in shares of HCP by 12.7% during the second quarter. Pensionfund DSM Netherlands now owns 106,593 shares of the real estate investment trust’s stock valued at $3,409,000 after purchasing an additional 12,000 shares during the last quarter. Institutional investors own 95.80% of the company’s stock.
NYSE HCP traded down $0.89 during mid-day trading on Friday, reaching $33.64. The stock had a trading volume of 4,003,528 shares, compared to its average volume of 2,801,829. HCP, Inc. has a 1 year low of $26.58 and a 1 year high of $37.93. The stock has a market cap of $17.57 billion, a PE ratio of 18.48, a price-to-earnings-growth ratio of 6.81 and a beta of 0.22. The company has a fifty day moving average price of $36.24 and a 200 day moving average price of $33.42. The company has a debt-to-equity ratio of 1.01, a current ratio of 0.81 and a quick ratio of 0.81.
HCP (NYSE:HCP) last announced its quarterly earnings data on Wednesday, October 30th. The real estate investment trust reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of $0.43 by ($0.52). HCP had a return on equity of 12.78% and a net margin of 43.66%. The firm had revenue of $538.00 million during the quarter, compared to analysts’ expectations of $503.65 million. During the same quarter in the previous year, the firm earned $0.44 earnings per share. HCP’s revenue was up 18.0% on a year-over-year basis. As a group, equities research analysts expect that HCP, Inc. will post 1.75 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Tuesday, November 19th. Shareholders of record on Monday, November 4th will be given a $0.37 dividend. This represents a $1.48 dividend on an annualized basis and a yield of 4.40%. The ex-dividend date of this dividend is Friday, November 1st. HCP’s dividend payout ratio (DPR) is presently 81.32%.
In other HCP news, COO Thomas Klaritch sold 35,014 shares of HCP stock in a transaction that occurred on Wednesday, September 4th. The shares were sold at an average price of $36.02, for a total value of $1,261,204.28. Following the completion of the sale, the chief operating officer now owns 230,529 shares of the company’s stock, valued at approximately $8,303,654.58. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 0.13% of the company’s stock.
Several equities analysts have recently issued reports on HCP shares. Barclays lifted their target price on shares of HCP from $37.00 to $39.00 and gave the company an “overweight” rating in a report on Wednesday, October 2nd. Zacks Investment Research upgraded shares of HCP from a “hold” rating to a “buy” rating and set a $39.00 target price for the company in a report on Monday, October 14th. TheStreet upgraded shares of HCP from a “c+” rating to a “b-” rating in a report on Friday, August 2nd. JPMorgan Chase & Co. upgraded shares of HCP from a “neutral” rating to an “overweight” rating and lifted their target price for the company from $35.00 to $38.00 in a report on Tuesday, October 8th. Finally, Stifel Nicolaus boosted their price objective on shares of HCP from $34.00 to $37.00 and gave the stock a “buy” rating in a report on Tuesday, September 3rd. They noted that the move was a valuation call. Two investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $36.78.
HCP, Inc is a fully integrated real estate investment trust (REIT) that invests in real estate serving the healthcare industry in the United States. HCP owns a large-scale portfolio primarily diversified across life science, medical office and senior housing. Recognized as a global leader in sustainability, HCP has been a publicly-traded company since 1985 and was the first healthcare REIT selected to the S&P 500 index.
See Also: Hedge Funds
Receive News & Ratings for HCP Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCP and related companies with MarketBeat.com's FREE daily email newsletter.